Vera (VERA) Q2 Net Loss Widens 127%
Vera Therapeutics (NASDAQ:VERA), a biotechnology company developing treatments for serious immunologic diseases, released results for the quarter on August 5, 2025. The most notable news was its widening net loss to $76.5 million, or $1.20 per share (GAAP), compared to analyst expectations for a GAAP loss of $0.82 per share. While the company posted headline revenue of $76.5 million (GAAP). Results show accelerated spending as the company moves closer to a planned regulatory filing for its lead drug candidate. The quarter highlighted both significant progress in clinical trials and notable increases in research and development expenses.
Source: Analyst estimates for the quarter provided by FactSet.
Vera Therapeutics is a clinical-stage biotechnology company focused on developing therapies for serious immunological diseases, most notably Immunoglobulin A Nephropathy (IgAN)—a chronic kidney condition. Its lead drug candidate, atacicept, is a dual BAFF/APRIL inhibitor designed to modify the course of IgAN, a disease with few options for disease-modifying treatment. The company's progress with atacicept is the main driver of its business, with a strategy built around advancing this drug through clinical trials and regulatory submissions.
Source Fool.com
